209 related articles for article (PubMed ID: 22851038)
21. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas.
Cakir A; Isik Gonul I; Ekinci O; Cetin B; Benekli M; Uluoglu O
Pathol Res Pract; 2017 Mar; 213(3):227-234. PubMed ID: 28215639
[TBL] [Abstract][Full Text] [Related]
22. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
[TBL] [Abstract][Full Text] [Related]
23. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.
Umekita Y; Ohi Y; Souda M; Rai Y; Sagara Y; Sagara Y; Tamada S; Tanimoto A
Diagn Pathol; 2011 Apr; 6():36. PubMed ID: 21496280
[TBL] [Abstract][Full Text] [Related]
24. A gene expression signature identifies two prognostic subgroups of basal breast cancer.
Sabatier R; Finetti P; Cervera N; Lambaudie E; Esterni B; Mamessier E; Tallet A; Chabannon C; Extra JM; Jacquemier J; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 Apr; 126(2):407-20. PubMed ID: 20490655
[TBL] [Abstract][Full Text] [Related]
25. Expression of androgen receptors in primary breast cancer.
Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS
Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463
[TBL] [Abstract][Full Text] [Related]
26. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.
Berclaz G; Altermatt HJ; Rohrbach V; Siragusa A; Dreher E; Smith PD
Int J Oncol; 2001 Dec; 19(6):1155-60. PubMed ID: 11713584
[TBL] [Abstract][Full Text] [Related]
27. A subset of breast cancer predisposes to brain metastasis.
Shao MM; Liu J; Vong JS; Niu Y; Germin B; Tang P; Chan AW; Lui PC; Law BK; Tan PH; Tse GM
Med Mol Morphol; 2011 Mar; 44(1):15-20. PubMed ID: 21424932
[TBL] [Abstract][Full Text] [Related]
28. Cytokeratin expression profile in gastric carcinomas.
Kim MA; Lee HS; Yang HK; Kim WH
Hum Pathol; 2004 May; 35(5):576-81. PubMed ID: 15138932
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
30. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.
Chen Y; Cui T; Yang L; Mireskandari M; Knoesel T; Zhang Q; Pacyna-Gengelbach M; Petersen I
Oncology; 2011; 80(5-6):333-40. PubMed ID: 21791943
[TBL] [Abstract][Full Text] [Related]
33. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
35. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
36. Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression.
Naka T; Iwamoto Y; Shinohara N; Chuman H; Fukui M; Tsuneyoshi M
Mod Pathol; 1997 Jun; 10(6):545-51. PubMed ID: 9195570
[TBL] [Abstract][Full Text] [Related]
37. Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer.
Woelfle U; Sauter G; Santjer S; Brakenhoff R; Pantel K
Clin Cancer Res; 2004 Apr; 10(8):2670-4. PubMed ID: 15102669
[TBL] [Abstract][Full Text] [Related]
38. Expression of cytokeratins in glioblastoma multiforme.
Terada T
Pathol Oncol Res; 2015 Jul; 21(3):817-9. PubMed ID: 25633990
[TBL] [Abstract][Full Text] [Related]
39. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
40. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
